President of R&D Judith Dunn resigns; position eliminated; CEO assumes direct oversight

Fulcrum Therapeutics, Inc.

Dr. Judith Dunn resigns as president, R&D; separation agreement signed October 14, 2022.
Dunn remains employed through Jan 3, 2023, then provides biotech consulting in transitional capacity.
Clinical development organization now reports directly to CEO Bryan Stuart; president R&D role eliminated.
Company continues search for Chief Medical Officer as previously announced.
Extended 6-month exercise period for stock options post-separation.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Judith A. Dunn

president, research and development

FULC · Fulcrum Therapeutics, Inc.

Effective: 2022-10-14
Filed: October 19, 2022, 7:59 PM ET

Dr. Judith A. Dunn entered into a separation agreement subsequent to Dr. Dunn’s resignation from her position as president, research and development.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Judith A. Dunn resigned as president, research and development at Fulcrum Therapeutics, Inc..

Action: resigned
Role: president, research and development

Exact text from the filing

Dr. Judith A. Dunn entered into a separation agreement subsequent to Dr. Dunn’s resignation from her position as president, research and development.

View on SEC.gov

Fulcrum Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-265260

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.